Cargando…
Prospects of Curcumin Nanoformulations in Cancer Management
There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer developm...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777756/ https://www.ncbi.nlm.nih.gov/pubmed/35056675 http://dx.doi.org/10.3390/molecules27020361 |
_version_ | 1784637143410278400 |
---|---|
author | Amekyeh, Hilda Alkhader, Enas Sabra, Rayan Billa, Nashiru |
author_facet | Amekyeh, Hilda Alkhader, Enas Sabra, Rayan Billa, Nashiru |
author_sort | Amekyeh, Hilda |
collection | PubMed |
description | There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer development and progression. Unfortunately, its use is limited due to its hydrophobicity, low bioavailability, chemical instability, photodegradation, and fast metabolism. Nanoparticles (NPs) are drug delivery systems that can increase the bioavailability of hydrophobic drugs and improve drug targeting to cancer cells via different mechanisms and formulation techniques. In this review, we have discussed various CUR-NPs that have been evaluated for their potential use in treating cancers. Formulations reviewed include lipid, gold, zinc oxide, magnetic, polymeric, and silica NPs, as well as micelles, dendrimers, nanogels, cyclodextrin complexes, and liposomes, with an emphasis on their formulation and characteristics. CUR incorporation into the NPs enhanced its pharmaceutical and therapeutic significance with respect to solubility, absorption, bioavailability, stability, plasma half-life, targeted delivery, and anticancer effect. Our review shows that several CUR-NPs have promising anticancer activity; however, clinical reports on them are limited. We believe that clinical trials must be conducted on CUR-NPs to ensure their effective translation into clinical applications. |
format | Online Article Text |
id | pubmed-8777756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87777562022-01-22 Prospects of Curcumin Nanoformulations in Cancer Management Amekyeh, Hilda Alkhader, Enas Sabra, Rayan Billa, Nashiru Molecules Review There is increasing interest in the use of natural compounds with beneficial pharmacological effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly effective against some cancers through its ability to regulate signaling pathways and protein expression in cancer development and progression. Unfortunately, its use is limited due to its hydrophobicity, low bioavailability, chemical instability, photodegradation, and fast metabolism. Nanoparticles (NPs) are drug delivery systems that can increase the bioavailability of hydrophobic drugs and improve drug targeting to cancer cells via different mechanisms and formulation techniques. In this review, we have discussed various CUR-NPs that have been evaluated for their potential use in treating cancers. Formulations reviewed include lipid, gold, zinc oxide, magnetic, polymeric, and silica NPs, as well as micelles, dendrimers, nanogels, cyclodextrin complexes, and liposomes, with an emphasis on their formulation and characteristics. CUR incorporation into the NPs enhanced its pharmaceutical and therapeutic significance with respect to solubility, absorption, bioavailability, stability, plasma half-life, targeted delivery, and anticancer effect. Our review shows that several CUR-NPs have promising anticancer activity; however, clinical reports on them are limited. We believe that clinical trials must be conducted on CUR-NPs to ensure their effective translation into clinical applications. MDPI 2022-01-07 /pmc/articles/PMC8777756/ /pubmed/35056675 http://dx.doi.org/10.3390/molecules27020361 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Amekyeh, Hilda Alkhader, Enas Sabra, Rayan Billa, Nashiru Prospects of Curcumin Nanoformulations in Cancer Management |
title | Prospects of Curcumin Nanoformulations in Cancer Management |
title_full | Prospects of Curcumin Nanoformulations in Cancer Management |
title_fullStr | Prospects of Curcumin Nanoformulations in Cancer Management |
title_full_unstemmed | Prospects of Curcumin Nanoformulations in Cancer Management |
title_short | Prospects of Curcumin Nanoformulations in Cancer Management |
title_sort | prospects of curcumin nanoformulations in cancer management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777756/ https://www.ncbi.nlm.nih.gov/pubmed/35056675 http://dx.doi.org/10.3390/molecules27020361 |
work_keys_str_mv | AT amekyehhilda prospectsofcurcuminnanoformulationsincancermanagement AT alkhaderenas prospectsofcurcuminnanoformulationsincancermanagement AT sabrarayan prospectsofcurcuminnanoformulationsincancermanagement AT billanashiru prospectsofcurcuminnanoformulationsincancermanagement |